Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: Immunocytokines: the long awaited therapeutic magic bullet in rheumatoid arthritis? | Available online http content 11 6 132 Editorial Immunocytokines the long awaited therapeutic magic bullet in rheumatoid arthritis Fons A van de Loo and Wim B van den Berg Rheumatology Research and Advanced Therapeutics Department of Rheumatology Radboud University Nijmegen Medical Centre Nijmegen 6525 GA The Netherlands Coresponding author Wim B van den Berg Published 6 November 2009 Arthritis Research Therapy 2009 11 132 doi ar2835 This article is online at http content 11 6 132 2009 BioMed Central Ltd See related research by Schwager et al. http content 11 5 R142 Abstract Modulatory cytokines such as IL-4 and IL-10 looked promising biologicals but suffered from poor exposure at the inflamed joints when administered via the patient-friendly subcutaneous route. Immunocytokines have now been engineered with tissue targeting potential and are a possible solution to this problem although challenges still exist. Local inflammatory processes cause destruction of extracellular matrix ECM components leading to neo-eptitopes and or elicit the synthesis of new ECM components. This makes ECM elements interesting targets for antibody-mediated recognition and retention to achieve higher levels of immunocytokines at the site of therapeutic interference. The study presented by Schwager and colleagues shows that targeted delivery of IL-10 is more efficacious in experimental arthritis. Clinical studies are warranted to show whether this strategy works for all rheumatoid arthritis patients or is better for subgroups with a defined ECM phenotype. In principle the scFv-targeting system is plastic enough to allow for personalized strategies. Immunocytokines The successful introduction of biologicals such as neutralizing anti-TNF-antibodies in the treatment of rheumatoid arthritis has paved the way for using immunocytokines in non-lethal diseases. The study of Kathrin Schwager and .
